https://pro.boehringer-ingelheim.com/sg/ 2024-12-20T07:06:56+00:00 daily 1.0 https://pro.boehringer-ingelheim.com/sg/bipdf/empagliflozin-cv-outcomes-across-uacr 0.5 https://pro.boehringer-ingelheim.com/sg/dabigatran-etexilate/safetycontent/sg-pradaxa-safety-info 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/discover-common-link-interstitial-lung-diseases 2024-12-13T12:48:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/linagliptin/safetycontent/sg-trajenta-safety-info 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/glyxambi/cvot 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/mechanism-action/approved-anti-fibrotic-known-and-established-mechanism 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/giotrif/safetycontent/sg-giotrif-safety-info 2026-02-13T09:39:09+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/ofev-reduces-risk-acute-exacerbations-seen-inbuild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/spiolto/safetycontent/sg-spiolto-safety-info 2026-02-13T09:38:23+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/telmisartan/safetycontent/sg-micardis-safety-info 2024-12-13T13:24:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/ofev-first-and-only-approved-therapy-pf-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/empagliflozin/safetycontent/sg-jardiance-safety-info 2024-12-13T13:27:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/exploratory-analysis-suggests-ofev-may-extend-life-expectancy 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/safety/management-ofev-related-diarrhoea 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-focus-autoimmune-ilds 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/dosage/offer-your-patients-one-capsule-twice-daily 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-diagnosis-treatment-atsersjrsalat-guideline 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/once-lung-function-lost-ipf-it-lost-forever 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/scalp-lesion-management 2024-12-13T13:44:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/ofev-slows-fvc-decline-regardless-baseline-fvc-impairment 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/stomatitis-management 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/learn-how-acute-exacerbation-ipf-can-impact 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-upswing-sequential-cohort 2024-12-16T12:14:56+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/ofev-significantly-reduces-risk-ae-ipf-pooled-inpulsis-1-and-2 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prescribing-information/empagliflozin-jardiance-prescribing-information 2024-12-13T13:46:56+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ofev-ae-management-diarrhoea-infographic 2026-02-13T09:36:40+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/ae-management-focus-diarrhoea 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/consistent-treatment-effect-ofev-irrespective-disease-stage 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/ae-management-focus-paronychia 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/xerosis-management 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/telmisartan/video 2024-12-13T14:06:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/ae-management-focus-skin-rash 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing 2024-12-13T14:07:54+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/safety 2024-12-13T14:08:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety 2024-12-13T14:08:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis 2024-12-13T14:09:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy 2024-12-13T14:14:28+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prescribing-information 2024-12-13T14:19:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/mechanism-action 2024-12-13T14:20:31+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/dosage 2024-12-13T14:21:21+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology 2024-12-20T07:11:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular 2024-12-20T07:12:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic 2024-12-20T07:14:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation 2024-12-20T07:15:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory 2024-12-20T07:17:37+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/prescribing-information 2023-08-08T13:58:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/telmisartan 2024-01-05T10:02:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib 2026-02-13T09:30:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/all-products 2026-03-11T11:42:05+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/resources 2024-12-20T11:34:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/resources/metabolic 2026-02-13T09:29:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/trajenta-sg-pi 2026-02-13T09:28:16+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/resources/cardiovascular 2024-12-17T12:45:37+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/resources/inflammation 2024-12-17T12:49:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/resources/oncology 2024-12-17T12:52:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/resources/respiratory 2026-02-13T09:26:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/contact-us 2026-03-09T14:56:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/terms-use 2025-12-01T08:35:35+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/videos 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/clinical-studies 2026-02-18T10:35:00+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif 2024-12-17T13:00:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin 2024-12-17T13:02:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/glyxambi 2024-12-17T13:04:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/linagliptin 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/dabigatran-etexilate 2024-01-02T12:18:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/regular-screening-critical-ild-can-develop-early 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/afatinib-treatment-nsclc-harbouring-uncommon-egfr 2024-12-16T12:15:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/dabigatran-etexilate/patient-materials 2024-12-13T15:09:46+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/dabigatran-etexilate/patient-materials/patient-alert-card 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/first-line-giotrif-data-over-30-real-world-studies-date 2024-12-17T11:01:54+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/vigilance-and-proactivity-are-critical-reducing 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/telmisartan/video/what-edge-telmisartan-over-other-arbs-terms-molecular-structure 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/telmisartan/video/cv-protection-benefits 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-significantly-reduces-relative-risk-disease-progression-or-death-vs-gefitinib 2024-12-17T11:02:47+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/consistent-efficacy-giotri-observed-across-real-world-studies 2024-12-17T11:03:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/telmisartan/video/delta-lock-structure 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/cv-risk-protection/emprise-new-data-release-ada-congress-2020 2025-12-18T10:08:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/efficacy/early-intervention-optimize-lung-function 2024-12-17T11:06:36+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/listen-our-experts-explain-importance-proactive-monitoring-patients-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto 2024-01-02T04:56:33+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/taiwan-real-world-data 2024-12-17T11:06:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/efficacy 2023-12-27T05:15:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tools-apps 2024-12-13T15:47:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tools-apps/sgjardiance-videoprof-ricardo-fontes-carvalho 2024-12-20T07:20:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-real-world-data-patientss-cns-involvement 2024-12-17T11:07:19+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/respimat 2023-12-28T11:58:21+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tools-apps/prof-ted-wu-t2d-patients-a1c-well-controlled-and-high-cv-risk-would-you-add 2024-12-13T15:56:55+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/guidelines 2023-12-27T06:17:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-treatment-nsclc-harbouring-uncommon-egfr-mutations-published-pooled-analysis-693 2024-12-17T11:09:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-delays-median-time-cns-progression-versus-chemotherapy 2024-12-17T11:09:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/listen-our-experts-share-their-thoughts-what-pf-ild-and-high-unmet-need-surrounding-disease 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tools-apps/prof-verma-esc-guidelines-2019-managing-t2d-cv-risk-changing-perspective-sglt2i 2024-12-16T05:53:28+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-ild-ppf-patients-ctd 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/south-korea-real-world-data 2024-12-17T11:09:38+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tools-apps/prof-wu-empagliflozin-cuts-insulin-need-patients-t2d 2024-12-16T06:04:02+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-identify-patients-ra-ild-who-can-benefit-ofev 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/ra-ild-delphi-consensus-screening-algorithm 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-efficacy-taiwan-and-korea 2024-12-17T11:17:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tools-apps/2022-ada-standard-care 2024-12-16T06:07:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/identifying-ild-patients-ra-dr-anna-hoffman-vold 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-efficacy-and-safety-elderly-egfrm-nsclc-patients 2024-12-17T11:23:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/real-world-evidence-giotrif-japan 2024-12-17T11:24:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/5-years-empa-reg-outcome 2024-12-16T06:12:23+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-safety-and-effectiveness-real-world 2024-12-17T11:25:02+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-brain-metastases-data-korea-and-taiwan 2024-12-17T11:33:25+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/empagliflozin-cardio-renal-metabolic-benefits 2024-12-16T06:26:01+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/real-world-effectiveness-giotrif-vs-osimertinib-data-japan 2024-12-17T11:33:47+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/largest-prospective-phase-iii-clinical-trial-patients-ssc-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/5-years-empa-reg-outcome/empa-kidneys-further-results-on-annual-rate-of-change-in-egfr 2024-12-16T06:39:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prescribing-information/empagliflozin-metfromin-hcl-jardiance-duo-prescribing-information 2024-12-16T06:44:28+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/sequential-treatment-afatinib-and-osimertinib-patients-egfr-mutation-positive-non-small 2024-12-17T11:34:13+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/listen-our-experts-share-their-insights-why-inbuild-important-study-patients-pf-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/key-managing-progression-ssc-ild-patients 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/inbuild-trial-population-and-baseline-medications 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/inbuild-trial-efficacy-autoimmune-ild-patients 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive 2024-12-17T11:34:56+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/pre-clinical-and-clinical-activity-giotrif-uncommon-egfr-mutations 2024-12-17T11:35:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/progressive-pulmonary-fibrosis-ppf-diagnosis-and-treatment-atsersjrsalat-guideline 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/safety/most-common-gi-related-adverse-events-ofevr-are-mild-moderate 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/guidelines-recommend-4-pillar-approach-managing-hfref-what-practical-approach 2025-01-16T14:35:54+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/how-has-hfpef-guidelines-evolved-advent-sglt2i-trials 2025-01-16T14:36:01+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/sequential-afatinib-and-osimertinib-patients-egfr-mutation-positive-video 2024-12-17T11:35:56+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/what-impact-sglt-2i-trials-hfpef 2025-01-16T14:38:55+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/uptake-subsequent-therapy-lux-lung-3-6-and-7 2024-12-17T11:36:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/what-impact-treatment-landscape-early-benefits-seen-emperor-trials 2025-01-16T14:41:16+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/what-do-we-know-about-consistency-results-empagliflozin-across-spectrum-ejection 2025-01-16T14:35:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/post-hoc-analyses-lux-lung-trials-giotrifr-followed-3rd-generation-tki 2024-12-17T11:36:50+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/what-role-empagliflozin-patients-hospitalized-heart-failure 2025-01-16T14:41:13+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/giotag-1st-global-study-show-feasibility-sequential-therapy-giotrif-followed-osimertinib 2024-12-17T11:37:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/japan-real-world-evidence-supports-sequential-treatment-use-upfront-2nd-generation-tki 2024-12-17T11:37:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-south-korea-reset-study 2024-12-17T11:37:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/totality-outcome-of-afatinib-giotrif-sequential-treatment-in-patients-with-egfrm-nsclc 2024-12-17T11:37:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/giotrif-followed-3rd-generation-tki-gioswing-sequential-cohort-combined-analysis 2024-12-17T11:37:58+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/safety/listen-our-experts-summarise-safety-profile-ofev-inbuild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/real-world-effectiveness-sequential-giotrif-osimertinib-data-giotag-and-reset-studies 2024-12-17T11:38:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/dosing-and-administration/results-realgido-global-real-world-study 2024-12-17T11:38:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view 2024-12-16T07:28:35+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/dosing-and-administration/giotrif-maintains-efficacy-despite-dose-modification 2024-12-17T11:38:36+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/learn-experts-why-it-important-reduce-ae-ipf 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/what-makes-sglt2i-ideal-hf-therapy 2025-01-16T14:35:56+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/lets-talk/what-are-kidney-benefits-empagliflozin-can-offer-heart-failure-patients 2024-12-16T07:31:46+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/dse-ee-video-monitoring-progression 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/efficacy/treatment-lamalaba-vs-labaics 2024-12-17T11:38:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/glyxambi/tool-apps 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/guidelines/gold-update-2019 2024-12-17T11:40:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/glyxambi/tool-apps/for-your-practice/3-convincing-cvots 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/guidelines/gold-2019-role-lama-laba 2024-12-17T11:40:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/efficacy/treatment-lamalaba-vs-lamalabaics 2024-12-17T11:41:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/side-effect-management-adherence-panel-discussion-dr-nicole-goh-ms-charlotte-ild-nurse 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/glyxambi/tool-apps/for-your-practice/2-proven-diabetic-medications 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/guidelines/new-gold-recommends-appropriate-use-ics 2024-12-17T11:08:42+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/glyxambi/tool-apps/for-your-practice/addressing-core-defects-t2d-powerful-glycemic-control 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/respimat/respimat-reusable 2024-12-17T11:07:40+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/recent-developments-management-ild-dr-felix-chua-royal-brompton-hospital 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/management-giotrif-adverse-events-real-world 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy 2024-01-02T13:54:51+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/expert-conversations/webinar-series/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-qa 2024-12-16T12:39:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-provides-3-years-long-term-response 2024-12-17T11:41:29+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/expert-conversations/webinar-series/6th-sso-asm-lung-track-evolving-treatment-landscape-egfrm-nsclc 2024-12-17T11:41:42+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/expert-conversations/webinar-series/6th-sso-asm-lung-track-afatinib-treatment-nsclc-uncommon-egfr-mutations 2024-12-17T11:41:55+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/tovito/tovito-phase-iii-clinical-trial-programme 2024-12-17T11:44:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/expert-conversations/webinar-series/6th-sso-asm-lung-track-sequencing-egfr-tkis-nsclc-treatment 2024-12-17T11:42:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/expert-conversations/efficacy-egfr-tkis-uncommon-mutations-qa 2024-12-17T11:43:00+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/expert-conversations/webinar-series/taking-cancer-webinar-lets-toast-maximising-time-egfr-tki-therapy-lecture 2024-12-17T11:43:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-vs-gefitinib-1st-line-treatment-egfrm-nsclc 2024-12-17T11:43:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/giotrif-delays-onset-risk-cns-progression 2024-12-17T11:43:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/safety/strategies-optimise-management-egfr-tki-related-side-effects 2024-12-17T11:43:55+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/how-are-crm-conditions-linked 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/tovito 2024-01-07T06:53:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/sequential-treatment-afatinib 2024-12-17T11:44:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/test-webinar-event2 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/what-is-the-clinical-relevance-of-broader-patient-population-studied-in-empa-kidney 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/giotag-1st-global-study-show-feasibility-sequential-therapy-giotrif-followed-osimertinib 2024-12-17T11:44:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/japan-real-world-evidence-supports-sequential-treatment-use-upfront-2nd-generation-tki 2024-12-17T11:45:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/endocrinology/shorts 2024-12-18T04:53:25+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spevigo/spevigo-one 2026-02-19T13:11:00+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/immunology/spevigo/redefining-gpp-with-prof-luis-puig 2026-02-19T13:12:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/events/nephrology/episode1-read-quick-facts-about-jardiance 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/webinar-single-registration-1 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/afatinib/efficacy/giotrif-in-uncommon-mutation-a-database-analysis-of-1000-nsclc-patients 2024-12-17T11:45:40+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/mechanism-action/discover-common-link-interstitial-lung-diseases 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties 2026-02-26T13:56:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/efficacy/inbuild-trial-efficacy-ra-ild-subgroup-analysis-dr-volkmann 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empa-kidney-stepping-next-level-chronic-kidney-disease-management 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts 2026-02-26T13:51:13+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/importance-mdd-managing-ctd-ild-patients-dr-volkmann 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/risk-factors-progressive-ra-ild-dr-volkmann 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/ild-ssc-when-consider-treatment-dr-volkmann 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/time-essence-suspect-fibrotic-interstitial-lung-disease 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/how-recognize-pulmonary-fibrosis-hrct-scans-rheum 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/upcoming-events 2026-02-26T13:51:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/patient-materials 2026-02-26T13:52:35+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/ra-ild-risk-calculator-home 2026-03-12T11:55:19+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/ra-ild-screening-algorithm 2025-02-13T04:42:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/ra-ild-risk-calculator 2025-02-13T11:05:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/differences-in-pulmonary-function-improvement-after-once-daily-laba-lama-fixed-dose-combinations-in-patients-with-copd 2026-02-11T10:34:42+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/triple-inhaled-therapy-at-two-glucocorticoid-doses-in-moderate-to-very-severe-copd 2026-02-11T10:33:42+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/once-daily-single-inhaler-triple-versus-dual-therapy-in-patients-with-copd 2026-02-11T10:32:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/a-pooled-analysis-of-mortality-in-patients-with-copd-receiving-dual-bronchodilation-with-and-without-additional-inhaled-corticosteroid 2026-02-11T10:31:39+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/efficacy-and-safety-of-umeclidinium-plus-vilanterol-versus-tiotropium-vilantero 2026-02-11T10:30:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/comparison-of-effectiveness-using-different-dual-bronchodilator-agents-in-chronic-obstructive-pulmonary-disease-treatment 2026-02-11T10:29:18+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/effectiveness-and-safety-of-copd-maintenance-therapy-with-tiotropium-olodaterol-versus-laba-ics-in-a-us-claims-database 2026-02-11T10:28:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/escalation-time-to-open-triple-combination-therapy-from-the-initiation-of-lama-versus-ics-laba-in-copd-management 2026-02-11T10:27:01+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/deposition-of-corticosteroid-aerosol-in-the-human-lung-by-respimat-soft-mist-inhaler-compared-to-deposition-by-metered-dose-inhaler-or-by-turbuhaler-dry-powder-inhaler 2026-02-11T10:25:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/use-of-respimat-soft-mist-inhaler-in-copd-patients 2026-02-11T10:24:38+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/global-initiative-for-chronic-obstructive-lung-disease 2026-02-11T10:23:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/differences-in-real-world-health-and-economic-outcomes-among-patients-with-copd-treated-with-combination-tiotropium-olodaterol-versus-triple-therapy 2026-02-11T10:21:48+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/reducing-and-managing-chronic-obstructive-pulmonary-disease-exacerbations-with-tiotropium-olodaterol 2026-02-11T10:20:23+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/tiotropium-olodaterol-shows-clinically-meaningful-improvements-in-quality-of-life 2026-02-11T10:18:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/dual-bronchodilation-with-tiotropium-olodaterol-further-reduces-activity-related-breathlessness-versus-tiotropium-alone-in-copd 2026-02-13T06:03:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/the-24-h-lung-function-profile-of-once-daily-tiotropium-and-olodaterol-fixed-dose-combination-in-chronic-obstructive-pulmonary-disease 2026-02-13T06:01:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/enhancing-exercise-tolerance-and-physical-activity-in-copd-with-combined-pharmacological-and-non-pharmacological-interventions-physacto-randomised-placebo-controlled-study-design 2026-02-13T06:00:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications/single-inhaler-triple-versus-dual-bronchodilator-therapy-in-copd-real-world-comparative-effectiveness-and-safety 2026-02-13T05:59:19+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/benefits-of-starting-an-sglt2i-upon-clinical-diagnosis-of-hf-subodh-verma 2026-02-26T14:27:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/why-is-empagliflozin-your-first-option-to-initiate-in-hf-subodh-verma 2026-02-26T13:07:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/making-an-impact-in-hf-episode-2-take-5-summary-video-day-2 2026-02-26T14:25:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory/spiolto/publications 2025-02-28T12:43:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/past-events/cardiology/episode-2-day-2 2026-02-26T14:25:29+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/making-an-impact-in-hf-episode-2-take-5-summary-video-day-1 2026-02-26T14:25:36+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/past-events/cardiology/episode-2-day-1 2026-02-26T14:25:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/tale-two-men 2026-02-13T05:58:05+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/not-all-dpp4i-are-the-same-safety-profile 2026-02-13T05:55:29+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/not-all-dpp4i-are-the-same-dosing 2026-02-13T05:40:23+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/not-all-dpp4i-are-the-same-simplicity 2026-02-13T05:38:19+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney 2024-12-20T07:50:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/what-are-the-major-challenges-today-with-treating-kidney-disease 2024-12-16T10:33:18+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/how-do-the-outcomes-of-the-empa-kidney-trial-help-patients-suffering-from-kidney-disease 2025-02-19T05:50:50+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/how-do-the-empa-kidney-results-add-up-to-the-existing-strong-scientific-evidence-of-empagliflozin 2024-12-16T10:35:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/what-is-the-most-impactful-outcome-that-was-shown-in-the-empa-kidney-trial 2024-12-16T10:35:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/how-do-you-interpret-the-results-of-the-primary-outcome-of-empa-kidney 2024-12-16T10:41:54+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/how-important-is-early-diagnosis-and-intervention-when-it-comes-to-ckd 2024-12-16T10:44:09+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/how-does-this-early-intervention-impact-the-heart 2024-12-16T10:44:54+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/how-do-you-interpret-the-importance-of-empa-kidney-results-with-regards-to-the-treatment-of-patients-with-ckd 2024-12-16T10:45:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/-how-relevant-is-the-broad-patient-population-within-empa-kidney-for-a-general-practitioner-daily-practice 2024-12-16T10:46:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/prof-christoph-wanner-take-on-empa-kidney/what-is-a-typical-patient-that-may-benefit-from-the-empa-kidney-trial-results 2024-12-16T10:47:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empowering-physicians-in-kidney-disease-management 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/specialty/ofev/4th-regional-ild-masterclass-agenda 2026-02-13T05:25:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiology/events/prime-summit-2024 2024-12-18T07:40:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/endocrinology/expert-opinions-regarding-uti-gti 2026-02-26T14:29:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/endocrinology/expert-opinions-regarding-egfr-dip 2026-02-26T14:29:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/endocrinology/diabetic-ketoacidosis 2026-02-26T14:30:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/endocrinolgy/practical-tips-animation-video-elderly-frailty 2026-02-26T14:30:35+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/endocrinology/professional-tips-on-t2d-patient-outcomes 2026-02-26T14:31:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/is-the-initial-egfr-dip-a-concern-angermann-and-carvalho 2026-02-26T13:08:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/toolbelt-video-clinical-relationship-between-heart-and-kidneys-angermann-and-carvalho-1 2026-02-26T14:35:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/sifrol-sg-pi 2026-02-13T05:22:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/cardiology 2026-02-26T13:57:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/mobic-sg-pi 2026-02-13T05:21:46+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/metalyse-sg-pi 2026-02-13T05:20:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/twynsta-sg-pi 2026-02-13T05:15:58+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/trajenta-duo-sg-pi 2026-02-13T05:11:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/praxbind-sg-pi 2026-02-13T05:08:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/pradaxa-sg-pi 2026-02-13T05:06:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/micardis-plus-sg-pi 2026-02-11T12:01:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance-sg-pi 2026-02-11T12:01:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance-duo-sg-pi 2026-02-11T12:00:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/glyxambi-sg-pi 2026-02-11T11:59:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/shorts/cardiology/lets-talk-impact-of-sglt2i-trials-in-hfpef 2026-02-26T14:25:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/jardiance/empact-mi-results-journal-paper 2026-02-11T11:57:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/immunology/newsletter-on-gpp-2nd-edition 2026-02-11T11:55:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/giotrif-sg-pi 2026-02-11T11:53:32+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products 2026-02-11T08:33:16+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/past-events 2026-02-26T13:51:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/cardiology/shorts 2024-12-16T11:50:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/cardiology/upcoming-events 2024-12-16T11:50:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/cardiology/past-events 2024-12-16T11:51:58+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/nephrology 2026-02-26T13:57:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/endocrinology 2026-02-26T13:58:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/primary-care 2026-02-26T13:58:25+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/endocrinology/patient-materials 2024-12-17T12:26:00+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/cardiology/resources 2024-12-17T12:26:33+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/primary-care/shorts 2024-12-17T12:27:32+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/primary-care/upcoming-events 2024-12-17T12:27:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/primary-care/patient-materials 2025-01-22T09:34:33+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/nephrology/resources 2024-12-18T06:48:40+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/micardis-sg-pi 2026-02-11T11:51:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/empa-kidney-study-page-from-ek22 2026-02-26T14:28:09+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/spevigo-vial-sg-pi 2026-02-11T11:51:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/actilyse-sg-pi 2026-02-11T11:49:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/nephrology/past-events 2024-12-17T12:41:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/primary-care/past-events 2024-12-17T12:41:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/nephrology/medication-guideline-for-t2dm 2025-01-17T10:20:55+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/endocrinolgy/4-steps-to-holistic-t2dm-management 2025-01-17T10:41:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/management-approach-for-people-with-t2d 2025-01-17T10:45:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/endocrinolgy/2022-kdigo-guideline-summary 2025-01-17T10:49:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/endocrinolgy/sick-days-rule-sadmans 2025-01-17T10:04:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/patient-materials/endocrinology/what-does-sglt2i-do 2025-01-17T10:51:39+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/patient-materials/endocrinology/tips-for-enjoying-the-benefits-of-taking-the-sglt2i2-without-worries 2025-01-17T10:55:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/patient-materials/cardiology/the-link-between-diabetes-the-heart-and-kidneys 2025-01-17T04:50:09+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources/endocrinology/t2dm-guideline 2025-01-17T10:37:08+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/not-all-dpp4i-are-the-same-dosing-simplicity 2026-02-11T11:47:25+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/which-is-the-simplest-dpp4i-in-your-clinical-practice 2026-02-11T11:44:35+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/evidences-on-combination-of-trajenta-jardiance 2026-02-11T11:42:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/updated-guidelines-on-dpp-4-inhibitors-for-type-2-diabetes 2026-02-11T11:39:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/type-2-diabetes-landscape-changes-with-dpp-4-inhibitors 2026-02-11T11:38:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/carmelina-cvot-renal-outcome-significance-explained 2026-02-11T11:36:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/is-dpp4i-suitable-for-admitted-patients 2026-02-11T11:35:32+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/which-type-of-patients-can-dpp4i-monotherapy-be-more-beneficial 2026-02-11T11:34:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/resources 2026-02-26T13:52:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/endocrinology/resources 2024-12-17T12:34:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/primary-care/resources 2024-12-17T12:33:46+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/vocrm-video-managing-initial-egfr-dip 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/immunology/spesolimab/gpp-reels-case-sharing-of-gpp-with-concomitant-plaque-psoriasis 2026-02-11T11:32:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/all-specialties/patient-materials/endocrinology/an-easy-guide-on-type-2-diabetes 2025-01-17T10:39:01+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/jardiance/cardiology/patient-materials 2024-12-17T12:33:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inpatient-gdmt-initiation-what-are-you-waiting-for 2024-12-20T08:07:18+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/hfpef-diagnosis-key-factors-to-consider 2024-12-13T16:48:36+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/empagliflozin-in-acute-hf-cardiorenal-outcomes 2024-12-13T16:47:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/hfpef-medications-keys-to-integration-and-compliance 2024-12-13T16:46:38+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/reduce-ami-trial-beta-blockers-post-mi-in-preserved-ef 2024-12-13T16:45:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance 2025-01-09T07:26:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/pcps-role-in-dkd-management-and-when-to-refer-to-endocrinologist 2026-02-19T13:09:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/what-does-kidney-function-preservation-in-empa-kidney-mean-to-you 2026-02-19T13:09:17+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/hcps-role-in-ckd-management-when-to-refer 2026-02-19T13:09:31+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/how-to-identify-progression-in-fibrotic-ild-radiology-expert-excerpt 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/rationale-for-early-antifibrotic-treatment-in-pf-ild-video-snippet 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/why-even-wait-until-there-is-10-relative-fvc-decline-physician-perspective-video-snippet 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/optimizing-treatment-of-patients-with-pf-ild-with-patient-case-study-expert-lecture 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-talk-tips-for-differentiating-hp-from-idiopathic-pulmonary-fibrosis 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-talk-what-are-the-treatment-options-for-patients-with-hp 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-talk-how-to-monitor-patients-with-hp-for-progression-and-identify-ppf-early 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-talk-how-to-treat-progressive-fibrotic-hp 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-talk-the-experts-practical-experience-with-ofev-nintedanib 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-talk-the-future-of-treatment-for-hp 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/unbranded/summary-empa-kidney-frailty-sub-analysis 2026-02-11T11:29:37+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/jardiance-patient-initiation-guide-patient 2026-02-11T11:27:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/jardiance-patient-initiation-guide-hcp 2026-02-11T11:28:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empowering-physicians-in-kidney-disease-management-webinar-9 2026-02-26T11:06:25+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/real-world-first-line-giotrif-for-egfrm-nsclc-updated-survival-data-from-korea 2025-10-16T08:20:28+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/summary-its-simple-its-all-about-them 2026-02-11T11:23:48+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/trajenta/patient-profiles-its-simple-its-all-about-them 2026-02-11T11:22:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiometabolic/events/prime-summit-3-2024 2024-12-20T08:14:50+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiometabolic 2024-07-18T12:28:40+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiometabolic/events 2024-07-18T12:37:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024/1st-event-post-webinar-video-lecture 2026-02-19T13:09:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/egfr-slope-surrogate-endpoint-in-kidney-trials 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/initiating-sglt2i-in-low-egfr-patients 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/role-of-screening-in-ckd-patient-outcomes 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/optimize-raasi-dose-with-sglt2i 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/synergistic-relationship-between-raasi-sglt2i 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/empa-kidney-benefits-of-empagliflozin-for-a1-a2 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/voice-of-crm/primary-care-physicians-transform-ckd-prognosis 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress-quiz 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/test-your-knowledge 2024-07-24T06:34:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/nerandomilast-mechanism-of-action 2026-02-26T12:24:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/fibroneer-ild 2026-02-26T12:25:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/the-interplay-of-vasculopathy-and-fibrosis-in-ssc 2026-02-26T12:25:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/vitalissce-trial 2026-02-26T12:26:18+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/anchor-ra 2026-02-26T12:26:32+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/vitalissce-trial/vitalissce-site-list 2026-02-26T12:26:47+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/aplar-congress/fibroneer-ild/fibroneer-ild-site-list 2026-02-26T12:27:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024/1st-event-post-webinar-video-qna 2026-02-19T13:07:17+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024/2nd-event-post-webinar-video-lecture 2026-02-19T13:07:10+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024/2nd-event-post-webinar-video-qna 2026-02-19T13:06:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/efficacy/vietnam-rwd-2024 2024-12-17T11:59:00+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress/button-testing 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/immunology/spesolimab/gpp-reels-2-use-of-iv-spesolimab-in-gpp-patient-who-failed-oral-systemic-agents 2026-02-19T13:05:17+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/jardiance/jardiance-patient-initiation-guide-bahasa-melayu 2026-02-19T13:25:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/jardiance/jardiance-patient-initiation-guide-chinese 2026-02-11T11:14:13+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/effect-of-sglt2i-on-reducing-hyperkalemia 2026-02-19T13:25:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/timestamp-test-page 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-wanner-3-early-kidney-screening-by-pcp 2026-02-19T13:05:35+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-green-1-key-summary-2022-easd-ada-2022-kdigo 2026-02-19T13:05:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance/dr-brendon-26-6yrs-delay-of-kidney-replacement-therapy 2026-02-19T13:04:16+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/latest-update-on-ctd-ild-management-by-dr-voon-ong 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-care-insights-from-an-ild-nurse-specialist 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/importance-of-early-referral-in-ctd-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/monitoring-patients-with-ctd-ild-best-practices 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/when-to-start-treatment-for-ssc-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/nintedanibs-role-in-ctd-ild-management 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/maintaining-treatment-adherence-in-ctd-ild 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/nintedanib-in-ra-ild-insights-from-the-inbuild-trial 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/oncology/giotrif/sequencing/real-world-evidence-giotrif-in-taiwan 2024-12-17T11:58:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/uacr-and-heart-failure 2026-02-11T10:52:41+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/summary-uacr-and-heart-failure 2026-02-19T13:24:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/hf-webinar 2025-01-17T11:41:31+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/expert-view/ild-masterclass-2024-post-event-newsletter 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-green-2-importance-of-egfr-and-uacr-screening 2026-02-19T13:03:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-jarvis-1-tips-for-sip-when-initiating-sglt2i-in-t2d 2026-02-19T13:03:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/sip-campaign-guidance/take-a-sip-prof-wanner-1-ero-renal-data 2026-02-19T13:03:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-esc-hfa-nt-probnp-thresholds-for-new-hf-diagnosis 2025-01-22T05:20:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-screening-for-cardiovascular-kidney-metabolic-syndrome 2025-01-22T05:20:16+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ild-test 2025-05-23T07:50:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-how-do-i-diagnose-and-manage-hfpef 2025-01-22T05:20:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-hfpef-scoring-and-interpretation 2025-01-22T05:19:50+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-comparative-sglt2i-rwe 2025-01-22T05:19:42+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-cardiorenal-effects-of-empagliflozin-after-ami 2025-01-22T05:19:32+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-t2d-sglt2-inhibitors-on-cardiovascular-outcomes 2024-12-13T15:30:01+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-synchronize-cvot-survodutide-obesity-phase-3-cvd-ckd 2024-12-20T08:39:48+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-glycemic-control-and-preventing-cardiovascular-disease 2024-12-13T15:27:12+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-survodutide-a-dual-agonist-for-obesity-and-mash 2024-12-13T15:25:21+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-empagliflozin-and-early-dkd-biomarkers-eurobeat-study 2024-12-13T15:24:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-empagliflozin-and-glp-1-receptor-agonists-combo-in-t2d 2024-12-13T15:22:09+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/empagliflozin-cv-outcomes-across-uacr 2026-02-19T13:24:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/immunology/gpp-reels-3-dr-latha 2026-02-19T12:48:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024/3rd-event-post-webinar-video-qna 2026-02-19T12:59:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024/3rd-event-post-webinar-video-lecture 2026-02-19T13:01:25+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/summary-long-term-effects-of-empagliflozin-in-ckd 2026-02-19T13:20:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/breathflix/video-series-1 2025-03-06T05:39:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/synchronize-cvot-survodutide-obesity-phase-3-cvd-ckd 2025-02-04T03:26:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/glycemic-control-and-preventing-cardiovascular-disease 2025-01-27T10:34:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/survodutide-a-dual-agonist-for-obesity-and-mash 2025-01-27T10:36:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/empagliflozin-and-early-dkd-biomarkers-eurobeat-study 2025-01-27T10:36:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/empagliflozin-and-glp-1-receptor-agonists-combo-in-t2d 2025-01-27T10:38:23+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/t2d-sglt2-inhibitors-on-cardiovascular-outcomes 2025-01-27T10:37:49+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-crm-symposium-2025/decade-of-protection-10-years-of-easy-choices 2025-03-27T14:15:17+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-crm-symposium-2025/breaking-silos-in-cardio-renal-care-heart-failure 2025-03-27T14:13:42+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/how-long-of-a-medication-half-life-would-you-prefer-for-your-patients 2025-02-07T10:27:09+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/what-would-you-seek-for-in-an-antihypertensive-medication 2025-02-07T10:27:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/which-would-be-a-preferred-antihypertensive-treatment-according-to-guidelines 2025-02-07T10:27:34+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/which-group-of-patients-would-you-consider-for-an-antihypertensive 2025-02-07T10:27:44+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/what-other-add-on-benefits-in-an-antihypertensive-that-you-would-want-for-your-patients 2025-02-07T10:27:53+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/If-you-had-a-choose-how-long-would-you-prefer-a-fuel-tank-to-last-before-needing-a-refill 2025-02-07T10:28:31+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/if-you-were-choosing-a-car-which-one-would-you-prefer 2025-02-07T10:28:50+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/if-you-were-repairing-a-leak-which-one-would-you-prefer 2025-02-07T10:29:01+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/when-installing-security-cameras-which-areas-would-you-prefer-to-cover 2025-02-07T10:29:19+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/if-you-were-picking-insurance-for-your-car-what-would-you-want 2025-02-07T10:29:13+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/significant-blood-pressure-reduction-sustained-over-24-hours1-2 2025-02-07T10:30:43+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/hypertensive-care 2025-02-07T10:30:51+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/2023-esh-hptn-guidelines-spcs-are-favoured-as-improves-treatment-adherence-and-increases-rate-of-bp-control 2025-02-07T10:30:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/add-on-benefits-in-antihypertensive-patients 2025-02-07T10:31:08+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta/ontarget-filled-the-cv-high-risk-patient-gap-in-the-cv-continuum 2025-02-07T10:31:17+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-crm-symposium-2025/kidneys-empowered-transforming-ckd-and-crm-care 2025-07-07T08:33:51+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/twynsta 2025-01-30T09:40:29+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ild-thank-you-page 2025-02-27T13:00:53+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/jardiance-10-years-hcp-testimonial-video-1 2026-02-19T12:47:24+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/meet-john-ipf-patient-journey 2025-02-26T12:06:58+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/meet-daniel-ra-ild-patient-journey 2025-02-26T12:07:06+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/nintedanib/about-pulmonary-fibrosis/meet-kim-ssc-ild-patient-journey 2025-02-26T12:07:17+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empowering-pharmacists-mastering-cardiovascular-metabolic-care 2025-12-03T06:18:45+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/erin-michos-why-should-hfpef-patients-be-managed-differently-from-hfref 2026-02-19T12:46:27+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/ricardo-carvalho-why-is-it-important-for-our-heart-failure-patients 2026-02-19T12:45:30+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/erin-michos-what-is-your-approach-in-managing-a-patient-with-hfpef 2026-02-19T12:42:04+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/ricardo-carvalho-what-are-your-major-considerations-and-approach-in-a-hf 2026-02-19T12:43:11+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/erin-michos-what-are-the-main-triggers-in-a-new-patient-that-would-make 2026-02-19T12:44:14+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolism/jardiance/ricardo-carvalho-in-patients-who-are-hospitalized-with-heart-failure 2026-02-19T12:40:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/crm-symposium-2025/decade-of-protection-10-years-of-easy-choices 2025-05-07T13:35:29+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/videos/beneath-the-ice-animated-video 2025-04-04T11:50:39+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/metabolic/empagliflozin/videos 2025-05-14T03:46:21+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/international-guidelines/2023-sard-ild-guideline-poster 2025-05-14T03:32:32+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/international-guidelines/2023-ssc-recommendations-infographic 2025-05-14T03:33:16+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/international-guidelines/2023-sard-ild-guideline-leaflet 2025-05-14T03:32:57+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/inflammation/international-guidelines 2025-05-14T03:31:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/test-page-ropu-screening-for-cardiovascular-kidney-metabolic-syndrome 2025-04-11T03:43:03+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/highlights-of-era-2025-2ndpage 2025-05-15T08:54:51+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/actilyse 2025-05-19T06:11:07+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/actilyse/act-smart-q 2025-05-27T14:39:58+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cardiovascular/metalyse 2025-05-19T06:57:21+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/vicadrostat-effective-across-kdogo-risk-classes-in-ckd 2025-06-30T05:03:26+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/test_markdown 2025-07-01T04:54:15+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/test-gws 2025-06-25T09:15:53+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/test-markdown 2025-06-30T11:52:59+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/respiratory-specialty/pfam-webinar-registration-page-2025 2025-09-11T05:10:22+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/products/tenecteplase-metalyse-sg-pi 2026-02-19T13:20:23+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/cvm-congress-2024 2024-12-13T09:41:52+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/ropu-crm-symposium-2025 2025-03-19T02:58:20+00:00 0.5 https://pro.boehringer-ingelheim.com/sg/crm-symposium-2025 2025-05-05T10:42:19+00:00 0.5